Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.

Date publication

mars 2016

Journal

Photodiagnosis and photodynamic therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FROCHOT Céline

Tous les auteurs :
Azaïs H, Schmitt C, Tardivel M, Kerdraon O, Stallivieri A, Frochot C, Betrouni N, Collinet P, Mordon S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26200606

Résumé

Ovarian cancer's prognosis remains dire after primary therapy. Recurrence rate is disappointingly high as 60% of women with epithelial ovarian cancer considered in remission will develop recurrent disease within 5 years. Special attention to undetected peritoneal metastasis during surgery is necessary as they are the main predictive factors of recurrences. Folate Receptor α (FRα) shows promising prospects in targeting ovarian cancerous cells and intraperitoneal photodynamic therapy (PDT) could be a solution in addition to macroscopic cytoreductive surgery to treat peritoneal micrometastasis. The aim of this preclinical study is to assess the specificity of a folate-targeted photosensitizer for ovarian peritoneal micrometastasis.

Mots clés

Animals, Cell Line, Tumor, Cell Survival, drug effects, Drug Evaluation, Preclinical, Female, Folate Receptor 1, metabolism, Folic Acid, administration & dosage, Injections, Intraperitoneal, Molecular Targeted Therapy, methods, Neoplasms, Glandular and Epithelial, drug therapy, Ovarian Neoplasms, drug therapy, Peritoneal Neoplasms, drug therapy, Photochemotherapy, methods, Photosensitizing Agents, administration & dosage, Porphyrins, administration & dosage, Rats, Rats, Inbred F344, Treatment Outcome

Référence

Photodiagnosis Photodyn Ther. 2016 Mar;13:130-8